NCT07268807Not yet recruiting
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease: A Single-Centre Retrospective Study
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
Previous clinical observations of potential benefit from Roxadustat in this complex patient population prompted this investigation Therefore, the investigators designed this retrospective, observational study to thoroughly investigate the effects of Roxadustat on heart failure treatment and ventricular remodelling in this specific patient population, aiming to provide new insights for patients management.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Zhongda Hospital
- Diseases
- Chronic kidney disease, Heart failure
- NCT number
- NCT07268807
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Dec 2025 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- participation in a drug clinical trial within one year.
Other illness
- comorbid myelodysplastic syndromes, multiple myeloma, hereditary hematologic diseases (e.g., thalassemia, sickle cell anaemia, pure red cell aplasia), hemosiderosis, hemochromatosis, or other disorders confirmed to cause anaemia due to erythrocyte destruction and/or abnormal hematopoietic function;
- bilateral nephrectomy, kidney transplantation within ≤6 months, or congenital kidney diseases (e.g., polycystic kidney disease);
- hypertrophic obstructive cardiomyopathy or congenital heart disease with right-to-left shunt;
- comorbid malignancy with an investigator-assessed life expectancy of less than 12 months;
- known allergy to the study drug (active ingredient or excipients);
Lab values
- haemoglobin level ≤45 g/L on two or more blood tests, a history of major bleeding within one year, or a history of anaemia corrected by blood transfusion;
Other
- pregnancy or lactation;
Who the study is looking for
- aged 18-85 years, regardless of gender;
- fulfilled the diagnostic criteria for heart failure and chronic kidney disease;
- haemoglobin level \<130 g/L for men or \<120 g/L for women at baseline;
- had regularly received Roxadustat for over one year;
- possessed complete clinical data, including information from pre-specified time points.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongda Hospital Southeast University Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.